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MUSINGS

The $1,000 genome, the $100,000 analysis?
Elaine R Mardis*
Having recently attended the Personal Genomes meeting
at Cold Spring Harbor Laboratories (I was an organizer
this year), I was struck by the number of talks that
described the use of whole-genome sequencing and
analysis to reveal the genetic basis of disease in patients.
These patients included a child with irritable bowel
disease, a child with severe combined immunodeficiency,
two siblings affected with Miller syndrome, and several
with cancers of different types. Although each presenter
emphasized the rapidity with which these data can now
be generated using next-generation sequencing instru
ments, they also listed the large number of people
involved in the analysis of these datasets. The required
expertise to ‘solve’ each case included molecular and
computational biologists, geneticists, pathologists and
physicians with exquisite knowledge of the disease and of
treatment modalities, research nurses, genetic coun
selors, and IT and systems support specialists, among
others. While much of the attendant effort was focused
on the absolute importance of obtaining the correct
diagnosis, the large number of specialists was critical for
the completion of the data analysis, the annotation of
variants, the interpretive ‘filtering’ necessary to deduce
the causative or ‘actionable’ variants, the clinical verifi
cation of these variants, and the communication of
results and their ramifications to the treating physician,
and ultimately to the patient. At the end of the day,
although the idea of clinical whole-genome sequencing
for diagnosis is exciting and potentially life-changing for
these patients, one does wonder how, in the clinical
translation required for this practice to become common
place, such a ‘dream team’ of specialists would be
assembled for each case. In other words, even if the cost
and speed of generating sequencing data continue their
precipitous decreases, the cost of ‘team’ analysis seems
unlikely to immediately follow suit. However, rather than
predicting from this reasoning that widespread diagnosis
by sequencing is unlikely to occur widely, it is perhaps
more fruitful to predict, in my opinion, what is probably
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required for it to occur. I therefore offer the following as
food for thought.
One source of difficulty in using resequencing
approaches for diagnosis centers on the need to improve
the quality and completeness of the human reference
genome. In terms of quality, it is clear that the clonebased methods used to map, assign a minimal tiling path,
and sequence the human reference genome did not yield
a properly assembled or contiguous sequence equally
across all loci. Lack of proper assembly is often due to
collapsing of sequence within repetitive regions, such as
segmental duplications, wherein genes can be found once
the correct clones are identified and sequenced. At some
loci, the current reference contains a single nucleotide
polymorphism (SNP) that occurs at the minor allele
frequency rather than being the major allele. In addition,
some loci cannot be represented by a single tiling path
and require multiple clone tiling paths to capture all of
the sequence variations. All of these deficiencies and
others not cited provide a less-than-optimal alignment
target for next-generation sequencing data and can
confound the analytical validity of variants necessary to
properly interpret patient-derived data. Hence, although
it is difficult work to perform, the ongoing efforts of the
Genome Resource Consortium [1] to improve the overall
completeness and correctness of the human reference
genome should be enhanced.
Along these lines, although projects such as the early
SNP Consortium [2], the subsequent HapMap projects [35], and more recently the 1,000 Genomes Project [6] have
identified millions of SNPs in multiple ethnic groups, there
is much more diversity to the human genome than single
base differences. In some ways, the broader scope of
‘beyond SNP’ diversity of the genome across human
populations remains mysterious, including common copy
number polymorphisms, large insertions and deletions,
and inversions. Mining the 1,000 Genomes data using
methods to identify genome-wide structural variation
should augment this considerably [7], with validation
playing an important role, as many methods are still
nascent. Lastly, devising clever ways to provide all such
classes of variants as a ‘searchable space’ for sequence data
alignment remains a significant challenge, as does the
development of sequence alignment algorithms that
facilitate the analysis of structurally complex loci.
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How well do we understand the functions encoded by
our genome? Certainly, comprehensive functional infor
mation about proteins, including the impact of muta
tions, is complete for relatively few genes. The develop
ment of high-throughput systems for biochemistry and
enzymology could have a dramatic impact on this
deficiency and would add vitality to these areas of scientific
endeavor. Efforts that annotate regulatory protein binding
sites, sites of RNA-mediated regulatory mechanisms, and
other motifs that contribute to transcriptional regulation
in the human genome must continue. Improved under
standing of these regions, and thus their annotation, will
require the power of model-organism-based systems to
identify and characterize functional proteins or
mechanisms that are shared with humans. We also must
transfer these findings into human cell experimental
systems that allow researchers to examine the impact of
the mutations or other alterations of the genome on
cellular pathways and the resulting disease biology. With
functional consequences in hand, we will begin to
understand and associate the clinical validity of genomic
variants, effectively enabling the correlation of variant(s)
with the resultant phenotype(s).
If our efforts to improve the human reference sequence
quality, variation, and annotation are successful, how do
we avoid the pitfall of having cheap human genome
resequencing but complex and expensive manual analysis
to make clinical sense out of the data? One approach
would emphasize the development of ‘clinical grade’
interpretational analysis pipelines to perform much of
the initial discovery from datasets derived from massively
parallel sequencing [8]. Although such pipelines already
exist in the research setting [9], manual checks and
orthogonal validation of variants are required because of
the ongoing development of the analytical approaches.
Towards patient diagnoses, such validation could initially
be performed in a clinical laboratory medicine setting,
but ultimately we must develop sophisticated analytical
approaches and quality filters that enable high-confidence
variant detection solely from the primary data. All dis
covered variants would then be interpreted in the context
of the ever-improving human genome annotation and
evaluated in the contexts of medical genetics, of demon
strated clinical validity, and of the pharmaceutical data
bases (when appropriate), to identify causative or thera
peutically actionable genes. Ultimately, as in medicine
today, the results will require interpretation by a
physician, which raises a separate but equally important
issue: the significant need to develop and implement
training programs in genomics for medical professionals.
Pathologists and genetic counselors will be the first in
line for training programs focused on genomic diag
nostics, and improving the genomics education of
medical students will also be a first priority. More
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challenging will be the genomics education of practicing
physicians and other medical professionals, many of
whom do not require genetics to perform their valuable
role in health care daily, but who will be confronted in
the near term by increasingly well informed patients who
expect their doctors to be as well versed as they are about
genome-guided diagnosis and treatment.
A final word on the important topic of patient access to
genome-guided medicine seems necessary and appro
priate. The current high cost of whole-genome sequen
cing and analysis relative to most clinical diagnostic
assays, coupled with the fact that these costs are not
currently reimbursed by insurers, might mean that only
those with the means to pay for the test will be allowed
access. Perhaps worse, those with the fattest wallets
might pay extra for a place higher in the queue, denying
earlier access to patients who more desperately need the
information. Although there are no easy answers here,
one plausible solution might be the establishment of
funds at major medical centers, where genome-guided
medicine is likely to be practiced first, that pay for the
genomic sequencing, diagnosis and associated costs and
thus allow equitable access to this new assay.
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